Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 7:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of a Web-Based Behavioral Intervention on Physical Activity Levels in Adolescents

NCT01433679
View directory record Official record
Conditions
Health Behavior, Adolescent Behavior, Motivation
Interventions
Zamzee Intervention
Behavioral
Lead sponsor
HopeLab Foundation
Other
Eligibility
11 Years to 14 Years
Enrollment
448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
6
States / cities
Los Osos, California • Oakland, California • Pismo Beach, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 29, 2026, 7:55 AM EDT
Recruiting Phase 4 Interventional

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

NCT07220382
View directory record Official record
Conditions
Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions
OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 7:55 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Altreno for Chest Rejuvenation

NCT04096742
View directory record Official record
Conditions
Photodamaged Skin, Photoaging
Interventions
tretinoin 0.05% lotion (Altreno), Vehicle
Drug · Other
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 29, 2026, 7:55 AM EDT
Terminated Phase 3 Interventional Results available

Safety Study of the VEGA UV-A System to Treat Ectasia

NCT01398839
View directory record Official record
Conditions
Ectasia
Interventions
VEGA UV-A Illumination System, Riboflavin
Device · Drug
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Atlanta, Georgia • Bloomington, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

OK432 (Picibanil) in the Treatment of Lymphatic Malformations

NCT03427619
View directory record Official record
Conditions
Lymphatic Malformations
Interventions
OK432
Drug
Lead sponsor
Richard JH Smith
Other
Eligibility
6 Months to 17 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
14
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prevention of GBS Colonization Via Immunity

NCT00128219
View directory record Official record
Conditions
Beta Haemolytic Streptococcal Infection
Interventions
GBS III-TT, Tetanus and diptheria toxoids vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
3
States / cities
Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 29, 2026, 7:55 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R®

NCT05333211
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Ortho-R/PRP
Drug
Lead sponsor
ChitogenX Inc
Industry
Eligibility
40 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Lauderdale, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris

NCT03433378
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin cream, 0.05%, RETIN-A® (tretinoin) cream, 0.05%, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows

NCT01891487
View directory record Official record
Conditions
Hypotrichosis
Interventions
Track A, Track B
Drug
Lead sponsor
ATS Clinical Research
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Renin-Aldosterone Axis in Postural Tachycardia Syndrome

NCT00962949
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome (POTS)
Interventions
Angiotensin II
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Not applicable Interventional

The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism

NCT02200263
View directory record Official record
Conditions
Ocular Albinism (OA), Oculocutaneous Albinism (OCA)
Interventions
Lutein plus Zeaxanthin, Placebo
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT02283853
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Interferon β-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 29, 2026, 7:55 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

NCT00254436
View directory record Official record
Conditions
Gastrointestinal Cancer, Rectal Cancer
Interventions
Procrit (epoetin alfa)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Not applicable Interventional

Chewing Gum Facilitates an Earlier Return to Bowel Function in Pediatric Scoliosis Patients: A Prospective Randomized Study

NCT02165436
View directory record Official record
Conditions
Scoliosis
Interventions
Chewing gum, Control
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 18 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 29, 2026, 7:55 AM EDT
Recruiting Phase 2 Interventional

RESvEraTrol in Parkinson's Disease (RESET)

NCT07592767
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Trans-Resveratrol
Drug
Lead sponsor
Georgetown University
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 29, 2026, 7:55 AM EDT
Terminated Phase 2 Interventional Results available

Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer

NCT02362451
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
Autologus elutriated monocyte placebo vaccine, Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Not applicable Interventional Results available

The Zeaxanthin and Visual Function Study

NCT00564902
View directory record Official record
Conditions
Age Related Macular Degeneration, Cognition Disorders
Interventions
3R 3'R Zeaxanthin, Lutein, Lutein and Zeaxanthin
Drug · Dietary Supplement
Lead sponsor
Chrysantis, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Not applicable Interventional

Biologics Anchoring Study

NCT03026153
View directory record Official record
Conditions
Moderate-to-severe Psoriasis
Interventions
Control Group Oral Survey 1, Intervention Group Oral Survey 2
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Early Phase 1 Interventional

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

NCT06062602
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
TAK-676, Carboplatin, 5-FU, Paclitaxel, TAK-676 + Carboplatin, Carboplatin + Paclitaxel, Carboplatin + 5-FU, TAK-676 + Carboplatin + 5-FU, TAK-676 + Carboplatin + Paclitaxel
Drug · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Shreveport, Louisiana • The Bronx, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

NCT04811664
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Moderna COVID-19 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 29 Years
Enrollment
1,923 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
51
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 29, 2026, 7:55 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

NCT03548064
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli, Immunisation
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 29, 2026, 7:55 AM EDT
Active, not recruiting Phase 2 Interventional

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

NCT01864109
View directory record Official record
Conditions
Newly Diagnosed Ewing Sarcoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Ifosfamide, Etoposide, Surgery, Radiation Therapy*, Temozolomide, Irinotecan, Mesna, Dexrazoxane, G-CSF
Drug · Device · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 40 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 29, 2026, 7:55 AM EDT
Completed Phase 3 Interventional

Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

NCT00006734
View directory record Official record
Conditions
Sarcoma
Interventions
filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, adjuvant therapy, conventional surgery, neoadjuvant therapy, brachytherapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
0 Years to 50 Years
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2023
U.S. locations
212
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 29, 2026, 7:55 AM EDT